MDRNA is a biotechnology company focused on the development and commercialization
of therapeutic products based on RNA interference (RNAi). We are building a
broad, flexible and cutting-edge drug discovery platform based on the premise
that no single RNAi technology or delivery approach can overcome the target
specific and indication specific challenges of down regulating protein expression
via a siRNA therapeutic. As a result, we have implemented a multi-faceted, multi-disciplinary
and multi-technological approach to discovering novel and proprietary RNAi-based
therapeutics we are confident will lead to clinical success.
We are employing proven RNAi technologies within a highly adaptable and cell-specific
delivery platform to down-regulate specific protein expression that causes disease.
This approach gives us the flexibility to fully optimize RNAi-based therapies
that target a wide range of diseases based on the unique characteristics of
the cells and organs involved.
IPONZ Approves MDRNA's Patent Application for siRNAs and Delivery Peptides
In this interview, AZoNano visits the Graphene Engineering and Innovation Centre to talk with Mark Dickie, Composite Applications Manager, about how the GEIC is helping to take graphene composite innovation out of the lab and into the wider industry.
In this interview, we speak with Stanford's Gu Group about their newly developed metal nanocluster-based material that's advancing nanoscale 3D printing.
Professor Andre Nel
In this interview, AZoNano speaks with Professor Andre Nel about his involvement in innovative research describing the development of a 'glass bubble' nanocarrier that could help drug formulations access pancreatic cancer cells.
The MiniCapt® Pro is a remote microbial air sampler that is ideal for the pharmaceutical manufacturing industry.
This product profile outlines the NanoRacer High-Speed AFM from Bruker JPK.
NMR spectroscopy is a characterization technique that is extensively used by chemical researchers.